Don’t Jump to Nurtec ODT for Migraine Prevention in Adults

August 2021

Nurtec ODT (rimegepant) will now be used for migraine PREVENTION in adults...in addition to acute treatment.

It blocks receptors of calcitonin gene-related peptide (CGRP), a vasodilator and pain sensitizer that spikes during migraine attacks.

Until recently, only the INJECTABLE CGRP antagonists (Aimovig, etc) were approved for prevention.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Alzheimer's Disease Educate Why Aduhelm Isn’t a Miracle for Alzheimer’s
Infectious Diseases Weigh Pros and Cons of First-Line Meds for C. diff
Obesity & Weight Loss Emphasize Lifestyle Changes for Obesity Before Wegovy
Potassium Be Armed With Tips to Get Potassium Levels Right
Migraine Don’t Jump to Nurtec ODT for Migraine Prevention in Adults
Colon Cancer Be Prepared for Expanded Colon Cancer Screening Recommendations
HIV & AIDS Optimize Care for People Living With HIV
Topicals Explain How Water Affects Topical or Transdermal Meds
Rheumatoid Arthritis Follow a “Treat-to-Target” Approach for Rheumatoid Arthritis
COVID-19 Lean Toward Tocilizumab as an Add-On to Steroids for COVID-19
Critical Care Re-Evaluate Goals for Targeted Temperature Management
COVID-19 Know the Latest About COVID-19 Monoclonal Antibodies